BioSpace News Archive

Breast cancer is a major public health problem in the United States and is associated with more than 40,000 deaths each year—most of them caused by metastasis, the spread of cancer to other parts of the body.

Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced it has entered into a strategic partnership and exclusive license agreement with DRS Daylight Solutions to expand the use of mid-infrared (mid-IR) technology in the bioprocessing market.

New York, NY and Providence, RI, Sept. 19, 2022 (GLOBE NEWSWIRE) -- As previously announced, on August 31, 2022, Aesther Healthcare Acquisition Corp. (“Aesther”) (NASDAQ: AEHA) entered into definitive merger agreement with Ocean Biomedical, Inc. Aesther announced today that it has paid, and that Continental Stock Transfer & Trust Company has received, $1,050,000 from Aesther representing the sum needing to be paid by Aesther to extend the date on which Aesther must consummate its initial b

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that an article highlighting preclinical data from BT8009, a Nectin-4 targeting Bicycle Toxin Conjugate, was published in Molecular Cancer Therapeutics.

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), today announced that Paul Levesque, President and Chief Executive Officer, will participate on the “Novel Targets in Oncology: Risk vs. Reward” panel, at the Cantor Oncology, Hematology & HemeOnc Conference to be held at the New York Palace Hotel, on Wednesday, September 28, 2022, at 9:00 a.m. ET, in New York City.

The Rockefeller Foundation announces it will commit US$15 million to the Global Fund to Fight AIDS, tuberculosis, and malaria ahead of the Fund’s Seventh Replenishment Conference on Wednesday, September 21.

Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, today announced a company name change to Imunon, Inc., reflecting the evolution of the Company’s business focus and its commitment to developing cutting-edge immunotherapies and next-generation vaccines to treat cancer and infectious diseases.

Astellas Venture Management LLC (President: William Watt, Ph.D., “AVM”), and Mission Bay Capital BioLabs (“MBC BioLabs”), today announced their collaboration on the “Astellas Future Innovator Prize” formerly known as the Astellas Golden Ticket competition.

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), today announced that England’s health technology assessment institute, the National Institute for Health and Care Excellence (NICE), has issued a final appraisal document (FAD) recommending BRUKINSA (zanubrutinib) for the treatment of Waldenström’s Macroglobulinemia (WM) in adults who have had at least one treatment, only if bendamustine plus rituximab is also suitable.

Virios Therapeutics, Inc. (Nasdaq: VIRI), announced today the pricing of its underwritten public offering of 10.0 million shares of its common stock at a public offering price of $0.50 per share, for gross proceeds of $5.0 million, before deducting underwriting discounts, commissions and offering expenses.